Analysis of drug prescriptions of patients with atrial fibrillation in combination with chronic kidney disease for compliance with STOPP/START criteria

The percentage of elderly and senile patients is growing every year. Among this cohort of patients, atrial fibrillation (AF) is one of the most common rhythm disorders. At the same time, AF repeatedly increases the risk of thromboembolic complications. The course of AF in elderly patients is often complicated by chronic kidney disease (CKD). When managing patients of this group, we often encounter polypragmasia, which affects the patient’s quality of life, increases the risk of falls, and potentially reduces life expectancy. In order to optimize pharmacotherapy, STOPP/ START criteria were developed.

The purpose of the study was the analysis of drug prescriptions in patients over 65 years of age with AF and CKD for compliance with the STOPP/ START criteria.

Material and methods. 339 case histories of the cardiology department and 180 case histories of patients of the therapeutic department of the Veterans of Wars multidisciplinary hospital were analyzed. In each department, patients were divided into 2 groups: patients with AF in combination with CKD C3a and patients with AF in combination with CKD C3b and C4.

Results. In the therapeutic department, 96.1% of the first group and 100.0% of the second group of patients were not prescribed drugs that are recommended for elderly patients (START criteria). 64.7% of patients from the first group and 53.8% of patients from the second group have potentially not recommended, but prescribed drugs (STOPP criteria) in the appointment lists In the cardiology department, the percentage of patients who did not have the recommended drugs (START criteria) in drug therapy was 92% in group 3, 97% in group 4. The percentage of patients who were prescribed potentially non-recommended drugs (STOP criteria) in group 3 45%, in group 4 48%.

Conclusion. Most elderly and senile patients with AF in combination with CKD have both START and STOPP criteria, which dictates a thorough analysis of the prescribed drug therapy.

1. Sumeet S.C., Rasmus H., Kumar N. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–847. https://doi:10.1161/CIRCULATIONAHA.113.005119

2. Kistler P.M., Sanders P., Fynn S.P. et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J. Am. Coll. Cardiol. 2004 Jul 7;44(1):109–16. https://doi:10.1016/j.jacc.2004.03.044

3. Lau D.H., Linz D., Sanders P. New Findings in Atrial Fibrillation Mechanisms. Card. Electrophysiol. Clin. 2019;11(4):563–571. https://doi:10.1016/j.ccep.2019.08.007

4. Andersson T., Magnuson A., Bryngelsson I.L. et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case-control study. Eur. Heart. J. 2013;34(14):1061–7. https://doi:10.1093/eurheartj/ehs469

5. Proietti M., Deirdre A.L., Lip G.Y.H. Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. EBioMedicine. 2016. V. 8. P. 309–316.

6. Guo Y., Gao J., Ye P. et al. Comparison of atrial fibrillation in CKD and non-CKD populations: A cross-sectional analysis from the Kailuan study. Int. J. Cardiol. 2019;277:125–129. https://doi:10.1016/j.ijcard.2018.11.098

7. Tapoi L., Ureche C., Sascau R. et al. Atrial fibrillation and chronic kidney disease conundrum: an update. J. Nephrol. 2019;32(6):909–917. https://doi:10.1007/s40620–019–00630–1

8. Go A.S., Fang M.C., Udaltsova N. et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119(10):1363–9. https://doi:10.1161/CIRCULATIONAHA.108.816082

9. Proietti M., Raparelli V., Olshansky B., Lip G.Y. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol. 2016;105(5):412–20. https://doi:10.1007/s00392–015–0936-y

10. Wang Y., Singh S., Bajorek B. Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation. Pharm Pract (Granada). 2016;14(2):706. https://doi:10.18549/PharmPract.2016.02.706

11. Jokanovic N., Tan E. C.K., Dooley M. J. et al. Prevalence and Factors Associated With Polypharmacy in Long-Term Care Facilities: A Systematic Review. J. Am. Med. Dir. Assoc. 2015;16(6):535.e1–535.e12. https://doi.org/10.1016/j.jamda.2015.03.003

12. Tkacheva O.N., Kotovskaya Yu.V., Runikhina N.K. et al. Clinical guidelines on frailty. Russian Journal of Geriatric Medicine. 2020;(1):11–46. https://doi.org/10.37586/2686–8636–1–2020–11–46

13. Sychev D.A. Polypharmacy in clinical practice: problem and solutions. 2nd ed.– St. Petersburg: TsOP «Professiya», 2018.– 272 p.

14. O’Mahony D., O’Sullivan D., Byrne S. et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2014;44(2):213–218. https://doi.org/10.1093/ageing/afu14

15. O’Mahony D. STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: origin and progress. Expert Rev. Clin. Pharmacol. 2020;13(1):15–22. https://doi.org/10.1080/17512433.2020.1697676

16. Baigent C., Blackwell L., Emberson J. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. https://doi:10.1016/S0140–6736(10)61350–5

17. Fleg J.L., Forman D.E., Berra K. et al. Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation. 2013;128(22):2422–46. https://doi:10.1161/01.cir.0000436752.99896.22

18. Qi K., Reeve E., Hilmer S.N. et al. Older peoples’ attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. Int. J. Clin. Pharm. 2015;37(5):949–57. https://doi:10.1007/s11096–015–0147–7

19. Todd A., Holmes H., Pearson S. et al. ‘I don’t think I’d be frightened if the statins went’: a phenomenological qualitative study exploring medicines use in palliative care patients, carers and healthcare professionals. BMC Palliat Care. 2016;15:13. https://doi:10.1186/s12904–016–0086–7

20. Streit S., Verschoor M., Rodondi N. et al. Variation in GP decisions on antihypertensive treatment in oldest-old and frail individuals across 29 countries. BMC Geriatr. 2017;17(1):93. https://doi:10.1186/s12877–017–0486–4

21. Farrell B., Tsang C., Raman-Wilms L. et al. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process. PLoS One. 2015;10(4): e0122246. https://doi:10.1371/journal.pone.0122246

22. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546–54. https://doi:10.1212/01.wnl.0000267275.68538.8d

23. Fang M.C., Go A.S., Chang Y. et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J. Am. Coll. Cardiol. 2011;58(4):395–401. https://doi:10.1016/j.jacc.2011.03.031

24. Li L., Geraghty O.C., Mehta Z. et al. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 390(10093):490–499. https://doi:10.1016/S0140–6736(17)30770–5

25. Ng K.H., Shestakovska O., Connolly S.J. et al. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age Ageing. 2016;45(1):77–83. https://doi:10.1093/ageing/afv156

26. Phelan E.A., Mahoney J. E., Voit J. C., Stevens J.A. Assessment and management of fall risk in primary care settings. Med. Clin. North. Am. 2015;99(2):281–93. https://doi:10.1016/j.mcna.2014.11.004

27. Gage B.F., Birman-Deych E., Kerzner R. et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am.J. Med. 2005;118(6):612 7. https://doi:10.1016/j.amjmed.2005.02.022

28. Man-Son-Hing M., Nichol G., Lau A., Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern. Med. 1999;159(7):677–85. https://doi:10.1001/archinte.159.7.677

29. Bangalore S., Steg G., Deedwania P. et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340–9. https://doi:10.1001/jama.2012.12559

30. Manrique C., Giles T.D., Ferdinand K.C., Sowers J.R. Realities of newer beta-blockers for the management of hypertension. J. Clin. Hypertens. (Greenwich). 2009;11(7):369–75. https://doi:10.1111/j.1751–7176.2009.00140.x

31. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. https://doi.org/10.15829/29/1560–4071–2020–4076

32. Holick M.F., Siris E.S., Binkley N. et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J. Clin. Endocrinol. Metab. 2005;90(6):3215–24. https://doi:10.1210/jc.2004–2364

33. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007;357(3):266–81. https://doi:10.1056/NEJMra070553

34. Chapuy M.C., Arlot M.E., Duboeuf F. et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N. Engl. J. Med. 1992;327(23):1637–42. https://doi:10.1056/NEJM199212033272305

35. Chapuy M.C., Pamphile R., Paris E. et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int. 2002;13(3):257–64. https://doi:10.1007/s001980200023

36. Trivedi D.P., Doll R., Khaw K.T. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003;326(7387):469. https://doi:10.1136/bmj.326.7387.469

37. Dawson-Hughes B., Harris S.S., Krall E.A., Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 1997;337(10):670–6. https://doi:10.1056/NEJM199709043371003

38. Sychev D.A., Orekhov R.E. Anticholinergic load scale as a method of combating polypharmacy in elderly and senile patients. Clinical Pharmacology and Therapy. 2016. V. 25. No. 4. P. 81–84.

39. Kukes V.G. Clinical pharmacology / ed. V.G. Kukesa, D.A. Sychev.– M .: GEOTAR-Media, 2015.– 1024 p.

40. Carnahan R.M., Lund B.C., Perry P. J. et al. Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J. Clin. Pharmacol. 2006;46(12):1481–6. https://doi:10.1177/0091270006292126

41. General principles of pharmacotherapy in elderly and senile patients: Guidelines / ed. HE. Tkacheva.– M.: Prometheus, 2019.– 66 p.

42. Gangji A.S., Cukierman T., Gerstein H.C. et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30(2):389–94. https://doi:10.2337/dc06–1789

43. Johnston S.S., Conner C., Aagren M. et al. Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(7):634–43. https://doi:10.1111/j.1463–1326.2012.01583.x

44. Signorovitch J.E., Macaulay D., Diener M. et al. Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs. Diabetes Obes Metab. 2013;15(4):335–41. https://doi:10.1111/dom.12031

45. Lanas A., Perez-Aisa M.A., Feu F. et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with non steroidalantiinflammatorydrug use. Am. J. Gastroenterol. 2015;100(8):1685–93. https://doi:10.1111/j.1572–0241.2005.41833.x

46. Tamura A. Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin gastroprotective agents: the OITA-GF study. QJM. 2011;104(2):133–9. https://doi:10.1093/qjmed/hcq169

47. Gudis K., Sakamoto C. The role of cyclooxygenase in gastric mucosal protection. Dig Dis Sci. 2005;50. Suppl1: S16–23. https://doi:10.1007/s10620–005–2802–7

48. Samsonov A.A., Andreev D.N. Gastropathy induced by non-steroidal anti-inflammatory drugs: pathogenetically substantiated approaches to prevention and therapy // Farmateka.2016; 2: 49–54.

49. Lanza F. L., Chan F.K., Quigley E.M. et al. Guidelines for prevention of NSAID-related ulcer complications. Am.J. Gastroenterol. 2009;104(3):728–38. https://doi:10.1038/ajg.2009.115